Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

BioArctic, Audiocast with teleconference, Q3'24

By Inderes11/14/2024, 8:30 AM
BioArctic

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Gunilla Osswald
00:01 - 20:47

Good morning and welcome to BioArctic AB's presentation for the third quarter of 2024. I have three key messages for today. The first one is that our projects are progressing very well, and I'm really excited about our BrainTransporter technology, where we have now been presenting data publicly. And I will show some of that data here today. Exidavnemab, our project for Parkinson's disease, has initiated Phase 2A with the screening of patients. My second message is that Leqembi sales are increasing, resulting in over 60% higher royalties for us compared to the previous quarter. The market in the US continues to grow, and Japan and China are above expectations, and the regulatory processes continue. And we are eagerly awaiting the CHMP opinion tomorrow. The third message is that we have a solid financial situation, so we can focus on progressing our projects in a good way. And then we take the next slide, please. I'm Gunilla Osswald. I'm the CEO of BioArctic AB and I will share today's presentation with our CFO, Anders Martin-Löf. We have also invited Paul Fresco, our Vice President of Science and Technology, who is the leader of our BrainTransporter program, and Anna Greenblatt, our Chief Commercial Officer. And they are here for the Q&A part of the presentation. Next slide please. BioArctic AB is listed at Nasdaq Stockholm Large Cap. And this is our disclaimer. Next slide please. As you know, BioArctic AB focuses on disease-modifying treatments for neurodegenerative disorders. And we are among the leaders in the world in two different areas. The first one is for highly selective antibodies targeting aggregated forms of misfolded proteins for Alzheimer's disease, Parkinson's disease, and ALS. We also have a BrainTransporter technology, which helps biological treatments cross the blood-brain barrier to achieve higher concentrations in the brain where the target is for the treatment. Our business model focuses on the innovation of new treatments for neurodegenerative disorders, and we are also becoming a platform company with our brain transporter technology. An important part of our business model is partnering, and we see three types of partnering. The first one is for large indications like Alzheimer's disease and Parkinson's disease, where our aim is to partner before phase two, or at least before phase three. For our brain transporter technology platform, we can also partner with companies that want their biologics to have increased brain penetration. Next slide please. So today I will start with the first message, which is about our pipeline. And how well that is progressing. And there are three things I want to start to mention. First, about our brain transporter technology. Some of our patents are now public. And we have preclinical data validating our BrainTransporter technology in transgenic mice and in non-human primates. The data demonstrate a rapid, broad, and deep brain distribution of the two compounds. The A-beta antibody Exidaprilamab, which is our most advanced alpha-synuclein program, has initiated the Phase 2a study in Parkinson's disease patients, and we plan to start dosing later this year. And we're also exploring the inclusion of MSA patients. Our founder, Professor Lars Lannfelt, received the Lifetime Achievement Award at the big CTAD Congress in Madrid. A couple of weeks ago, the Alzheimer's disease research community, along with experts, emphasized and acknowledged his great efforts for Alzheimer's disease patients with new innovative treatments like Lecanemab, which is based on his groundbreaking research in Alzheimer's disease. Next slide please. The brain has a natural barrier to protect it, called the blood-brain barrier. And that is making it difficult for treatments to get into the brain, especially biologicals, which are a little bit larger like antibodies. At BioArctic AB, we focus on brain disorders, and therefore this kind of technology is critical for us. We are highly engaged in this area, and we invest in developing new treatments with improved brain penetration. We utilize the transferrin receptor to achieve active transport of our antibodies across the blood-brain barrier. Our brain transporter-approved approach is unique in several ways. For example, where we bind to the transferrin receptor, the binding site is the protease-like domain of the transferrin receptor, and this is positioned near the cell membrane, which enhances the safety profile for hematology. Parameters are improved, especially with regard to reticulocytes. For example, the BrainTransporter technology will increase brain exposure of the antibody. It can provide a broader distribution in the brain, allowing it to reach deeper brain structures. A first blood-brain barrier transport results in rapid brain exposure and the potential for a fast effect. The increased exposure and broader distribution can potentially lead to a better effect as well. Lower doses can also result in better convenience for the patients, and we strive for subcutaneous administration. It could also lead to better safety due to lower doses and different distribution in the brain. Next slide, please. We see a stronger, broader, and deeper brain distribution with the approach. It has now been validated in transgenic mice and in non-human primates. In the picture to the left, you see a double transgenic mouse with a human transferrin receptor and the five times FAD mice. And they are overexpressing amyloid deposits in the brain. To the left, you see a brain where we have used a normal A-beta antibody, and you see some green of the antibody, especially in the ventricles. When we engineer the amyloid beta antibody and combine it with our brain transporter technology, then we get dramatically more antibody into the brain. As you can see in the green picture to the right. I think a picture says more than a thousand words. To the far right of this slide. You see some data from our non-human primate study. And you can see that we substantially increase brain exposure. We get substantially higher brain exposure of our beta amyloid antibody in different regions. And here we've shown, for example, the cortex and striatum. But it's also applicable for the hippocampus and other regions. And we see up to 70-fold increased levels versus the naked antibody. Importantly, when you work in this area, and as we see with several other transferrin receptor technologies, we need to note their effects. They have shown issues with hematology and reticulocyte decrease. Our safety profile so far looks very good without affecting hematology, including reticulocytes, as you can see down to the right. So in summary, I think we have very encouraging data, and we have now combined our technology with projects in all our disease areas with antibodies for Alzheimer's disease, Parkinson's disease, and ALS. And we are also starting to combine it with enzyme replacement therapies like with GCase, where we are aiming to address CNS symptoms of Gaucher disease. This area is very much in focus, and this is evident, for example, in recent deals within the industry. And we see increased interest from potential partners. Next slide please. Our alpha synuclein portfolio is also progressing very well, and I think there are many opportunities in several neuronal synucleinopathies, such as Parkinson's disease, Parkinson's disease dementia, Lewy body dementia, and prodromal stages. Um, and also orphan drug indications like multiple system atrophy. I think it's reassuring that biomarkers are now available to identify the right patients with pathological alpha-synuclein. And we will also use this in our phase two study with Exidavnemab. Next slide please. The phase two study with Exidavnemab will be performed in patients with mild to moderate Parkinson's disease. And we call the study EXiST. The design is a randomized, double-blind, placebo-controlled trial with both low and high doses compared to placebo. The primary endpoint is safety and tolerability. The key secondary endpoints are pharmacokinetics and immunogenicity. And then we have exploratory biomarker endpoints. Several of them. So, several biomarkers, both biochemical biomarkers as well as digital motor and cognition markers, are relevant for patients. And an important preparation for the next proof of concept study. The study will be performed in Spain and in Poland, and the screening of patients has already started. We plan to start treatment during this quarter. We are also exploring possibilities to add a new cohort of patients with MSA. Next slide please. So in summary of this part of the presentation, our portfolio is progressing really well. And today I've highlighted our BrainTransporter projects and Exidavnemab. And then next slide please. And we come to my second part of the presentation, which is about Leqembi. The number of patients treated with Leqembi continues to grow, and I think it's very reassuring to hear that the clinical safety experience is on par or better than reported in the phase three program. On the commercial side, royalties increased by more than 60% for the third quarter compared to the second quarter this year, resulting in royalties of about 70 million Swedish crowns to BioArctic AB. We see continued growth in the US market and an impressive growth in Japan and China, where it exceeds expectations. Eisai has lowered their outlook due to the slower uptake initially in the US, and Anders will discuss this further. On the regulatory side, Leqembi is approved and has now been launched in Hong Kong, Israel, the United Arab Emirates, and Great Britain. Regulatory authorities are reviewing Lecanemab files, and that's ongoing in 17 different markets and regions, including the EU. And as we know, we are waiting for the CHMP opinion tomorrow. Eisai has finalized the rolling submission of the subcutaneous autoinjector for maintenance dosing at the end of October. On the development side, um, Eisai is continuing to do a lot of different things. For example, the head study 345, the phase three study completed recruitment by mid-October. The study is for preclinical Alzheimer's disease individuals, meaning individuals with elevated levels of amyloid deposits in the brain. But they do not yet have any symptoms, and they will receive the treatment with either lecanemab or placebo for four years. During the latest Alzheimer's Congress, CTAD Eisai presented new data from the phase three Clarity AD study, and this further supports both early and maintained treatment. Next slide please. Lecanemab is the first disease-modifying treatment for Alzheimer's disease with full approval in the US, Japan, and China. And it's on its way to being established as a standard of care treatment for Alzheimer's patients. If we look at the US, intravenous administration every two weeks has been approved and broadly reimbursed since July last year. A supplementary BLA is under review for less frequent maintenance dosing once a month, with a PDUFA date in January next year. In October, Eisai completed the rolling submission of the new BLA for subcutaneous administration with an autoinjector for maintenance treatment, and Eisai is also preparing a submission for induction treatment with a subcutaneous autoinjector to be submitted after the approval of the subcutaneous maintenance treatment. As I said, in Japan and China, the launch is exceeding expectations, and in Europe we are waiting for the CHMP opinion following the reexamination, and we expect the information tomorrow. And of course, we hope it will be positive. So we also hope to provide it to some patients in Europe. Access to Leqembi, or Lecanemab, is now approved in a total of eight countries and regions and is under review in another 17 countries and regions. Next slide please. I would like to share with you some of the key highlights from the Congress for Alzheimer's disease, which is one of the largest Alzheimer's Congresses. And it was held in Madrid at the end of October. Eisai presented three years of long-term data with Lecanemab, which showed increased patient benefit with a maintained safety profile. We can see clear and meaningful long-term treatment effects. And that was shown over 36 months when all patients now have received lecanemab either from the start, which means three years of treatment, or if they had placebo in the core study, then they have been treated for 18 months. So if we look at the graph to the left, we see the benefit increase over time. The benefit was 0.45 on the CDR sum of boxes scale after 18 months, and it doubled to 0.95 after three years. Patients benefit if they start treatment early, as they then receive more benefits. And that's what you see in the green top curve. But we also see that patients can benefit by starting later, as demonstrated in the middle curve where the black line indicates the period they had placebo, and the green line shows when they started to receive lecanemab. And we can compare that with the purple curve, which is a matched historical control group from ADNI. And also, I think it's very reassuring to hear the experiences from key opinion leaders, from clinical practice, from both the US and Japan. They reported that Leqembi had a wide patient acceptance and compliance. Very few patients want to stop treatment. They also concluded that the treatment is safe, with no new safety findings reported, and that the side effects are manageable. The side effects in focus are especially ARIA-E and ARIA-H, and they are similar to those observed in the clinical studies, even though the treatment is now being used in clinical practice. They are mainly asymptomatic and transient, and occur during the first six months. Very few areas are reported after six months. The patient journey is improving in several ways, for example with blood-based biomarkers. Safety matters, of course, and approximately 18,000 patients have now been treated with Leqembi. And I think it's reassuring that no new safety findings have been reported and that there is a low frequency of ARIA after the first six months, and that the key opinion leaders concluded that these side effects are manageable with a lower or similar frequency than was seen in the clinical trials. Next slide please. More data were presented at Clarity AD supporting the need to start treatment earlier. And that could benefit patients more. And also to continue dosing at the Alzheimer's Congress called the AAIC in July. Then Eisai presented the graph to the left, which I think shows very encouraging data from a small substudy in patients with no or very low tau, which means that they are early in their disease. 60% of these patients had improved after 18 months, and more than 50% were still doing better after 36 months. We should, of course, be a bit careful since only 440 patients are part of this substudy. But I think it's encouraging and further emphasizes the importance of starting treatment early. Now at CTAD, at this Congress, Eisai presented the graph to the right. What we see here is that after 18 months of lecanemab treatment, there was a 51% less decline compared to placebo. And this is in contrast to the full population of the study, which showed a 27% less decline versus placebo. We see similar results also when we look at other scales measuring cognition and activities of daily living. I think also, it's very exciting, and we hear more and more patient stories with patients benefiting from Leqembi treatment. Next slide please. Lecanemab development continues with a subcutaneous autoinjector, which could make administration much more convenient and possible to give at home in an easier way. And I think this is of great support for the patients and for society. The blood-based biomarkers for diagnosis will also simplify the patient journey and help to identify patients in a much easier way than using PET scans and CSF samplings, which can sometimes be challenging. And this development is going really well. Professor Susanne Schindler from WashU. She presented data at CTAD on blood-based biomarkers, stating that prime time is now and that they are already being used for screening, and I think the usage for confirmation is not far away. It could be expected next year and onwards. And then again, earlier treatment has shown more benefit, which is encouraging for the phase three study. AHEAD 3-45. And in subjects who do not yet have symptoms but have elevated amyloid deposits in the brain. This study is already using blood-based biomarkers to identify the right patients, and recruitment has now been completed. Next slide, please. So, um, by that I hand over to the third key message about our solid finances, and I will hand over to Anders Martin-Löf.

Anders Martin-Löf
20:47 - 31:31

Thank you, Gunilla. I'll start to talk a little bit about the Leqembi revenues. On this slide, it's been known for a while that the global sales of Leqembi in the third quarter were roughly ¥10 billion, or $67 million. That means that our royalties that you see on the left-hand side increased to 69.8 million Swedish kronor. That's a 64% increase over the second quarter of 2024. Or if you like, 3,200% over the third quarter of 2023. So we're seeing very, very rapid growth in our royalty revenues. If we look at the different geographies, the sales in the US were ¥5.9 billion in the third quarter, or $39 million, and that's roughly 30% higher than in the second quarter. And it seems that there is a very good demand. Initially, it was thought that diagnosis with PET and CSF would be a bottleneck. That's what the market expected. That does not seem to be the case. And that has actually been facilitated by the start of the implementation of using blood-based biomarkers for pre-screening patients in the US. So even though PET capacity is fairly scarce, when you use blood-based biomarkers, you can pre-qualify the patients and you have a lot more patients that are actually positive when they do their PET scans. So that has helped the diagnostic process. And the inflow of patients is now fairly large, making it feasible to obtain reimbursement. However, what Eisai has observed lately is that there has been a bottleneck in infusion capacity. So they stated that they have roughly 6000 patients lined up that could not be treated due to the lack of infusion capacity. They are working really hard on that problem and have contracted more facilities, and the capacity is expected to increase by 90% in the following two quarters. So they're expecting to treat the 6000 patients that are lined up for treatment. But that has held back the sales in the US during the last few quarters. I think this also underlines the importance of subcutaneous administration. If Leqembi is going to grow to hundreds of thousands of patients, infusion capacity could become a really big problem in the world. But we are in a fortunate position that the subcutaneous version is evolving really, really well. Eisai is expecting approval for maintenance therapy using the subcutaneous version by mid-next year, with the induction therapy anticipated by the beginning of 2026. So, so I think these problems will be alleviated over time. If we then turn to Japan, we observed very rapid growth. 80% from the second quarter, up to ¥2.7 billion, or $80 million. They're now treating some 5,000 patients across 800 facilities, and that's almost half of what they're treating in the US, where they've been active for a much longer time. So, I think the Japanese market is doing really well here. I think it's interesting to note that they're now starting a direct to consumer campaign to raise awareness about mild cognitive impairment and to promote early diagnosis. And I think the largest growth area in the coming years will be mild cognitive impairment, especially since that's probably the period of the disease when we can have the largest impact. So I think what you see in Japan will be followed in other regions as you start to focus on these earlier disorder patients. They sold for about ¥1.2 billion in the first quarter, where it was actually on the market, so $8 million. So already up to 3,000 patients in China in the first quarter of sales, which is really, really strong here. Eisai is using a self-pay model. There is no reimbursement from the larger healthcare system. And they're relying solely on blood-based biomarkers and using a digital platform. And this is also a model that I think could be copied and used in different parts of the world over time. We will not see that short term, but in the longer term, I think blood-based biomarkers and the focus on MCI and using the subcutaneous version is where we are heading in the years to come. All in all, due to the slightly slower development in the US, they reduced their fiscal year forecast. It was ¥56.5 billion, or $370 million, and they reduced that down to ¥45 billion, or $280 million. And that means that they are expecting sales of roughly $170 million in the two quarters to come. Um, however, longer term, the mid and long-term forecasts have not been changed, and we still have the same belief in the potential of the product. There are a number of things that we have to sort out. It is a complicated product to administer in the beginning and that is now being sorted out. But longer term, those problems will diminish since we have a number of developments that will help the implementation of Leqembi treatment going forward. If we then turn to the next slide, I will comment on our financials. On the left-hand side, you see our net revenues, which decreased from the third quarter of 2023 from 209 to 77 million Swedish krona. Of course, in 2023, we received a significant milestone payment for the Japanese approval. So it's not really comparable. Uh, I should also mention that we're not expecting any milestone payments, uh, in the coming quarter. We didn't get anything in Q3 this year, and we will not get any milestones in the fourth quarter. Um, but I think you can also see the trend that during the year our revenues are growing, and that is what we expect to continue. Those are the royalty revenues that are growing over time. Uh, and that trend will, of course, continue. We also have some co-promotion revenues in there of 3 million that will grow if we get the approval. In Europe, we don't know that yet, but hopefully that will happen shortly if we get a positive CHMP opinion. Looking at the cost on the mid graph, you see that the operating expenses increased to 95 million from 78 million one year ago. R&D is now 72% of our total operating expenses. So it was 68 million in the third quarter of this year. That's roughly 100% higher than a year ago when it was 33 million. However, it's down from the second quarter when our R&D expenses were 84 million. And this is fairly lumpy. It goes up and down a little bit when we have larger payments for clinical trials and CMC work, but the long-term trend is that the cost will continue to increase on the R&D side as we are progressing our project portfolio. We are now, as I mentioned, starting our phase two trial with Exidavnemab. We're also investing heavily in our other programs, despite some of them currently falling behind, as they are making really good progress. . So you should expect growing R&D costs in the coming year. We were planning to increase our spending in marketing and sales, but we have held back some recruitments until we get the final CHMP opinion. If that's positive, you will see an increase in the next year. If not, probably not. Um, we have previously guided that the full year cost would be roughly 30 to 50% higher in 2024 compared to 2023. We're still in that range, and now I expect that the cost will be roughly 35 to 40% higher in 2024 versus 2023. If we then turn to the right-hand side, you see that the operating loss was 26 million Swedish kronor. Uh, and that's when we made a profit in the third quarter of 2023. Of course, that was driven by a milestone received in 2023 that we did not get now. But you also see, I think again, it's interesting to observe the trend that without any milestones, we are also decreasing our loss. So we're really starting to see the impact of growing royalties that are beginning to finance more and more of our R&D spending. If we turn to the next slide, you see that the net results were. Net result was 20 million. So that's roughly 6 million better than the operating result. And as we explained, by financial net on the middle graph, you can see that the cash flow from operating activities was -80 million. That's roughly 60 million lower than the net loss. And this is basically due to the delay of royalties, as we get paid for the royalties roughly two quarters after the sales have occurred. So we have a growing accounts receivable. So our current assets, containing these numbers, are roughly 110 million related to royalties. Um, on the right-hand side, you see our cash balance is still very strong. We have over 800 million, including short-term investments, at the end of the third quarter. Uh, we think that we will end the year with more than 700 million in cash and short-term investments. And going forward, we have mentioned this before. We will, uh, become profitable based on Leqembi royalties. Uh, so we will maintain a very, very strong financial situation going forward in the coming years. However, we will not talk today about exactly when we will become profitable. There are a number of moving parts, but long term this will lead to profitability. With that, I hand the word back to Gunilla for some closing remarks.

Gunilla Osswald
31:31 - 33:51

Thank you so much, Anders. So we are approaching the upcoming news flow and some closing remarks. So next slide please. The upcoming news flow. So this fourth quarter, we plan to start the Exidavnemab Phase IIa study in Parkinson's patients with the dosing. So we hope to be able to communicate that. And then we're also awaiting, of course, the CHMP opinion on Lecanemab in the EU tomorrow. We do not yet know the outcome, and I think it's not decided yet. But of course we are hoping for a positive outcome and then a potential approval by the European Commission within 60 to 70 days in January next year. We also expect a response from the FDA regarding less frequent monthly IV maintenance dosing of Leqembi in the US, and regarding the subcutaneous autoinjector, we expect responses next year regarding maintenance dosing and also for the induction treatment in 2026. And of course, we're also hoping for further regulatory approvals and launches in several other countries and regions. Next slide please. So to summarize today's presentation, our pipeline is progressing very well, and we are very encouraged by the BrainTransporter data that has been presented, generating a lot of interest. We're looking forward to the Exidavnemab phase to start. And Leqembi is approved in eight geographies and now launched in seven of them, including the US, China, and Japan, where there are very large patient populations with early Alzheimer's disease. And even a small part of the population will be significant. And it's gratifying that we can help many patients. Lecanemab royalty revenues continue to grow as sales increase. And we heard Anders explain that our finances remain solid, and we have about 800 million Swedish crowns in cash, which I think is great. So we can focus on driving the project forward towards patients. Next slide please. So with that, I say thank you so much for your attention, and we're happy to take some questions.

Operator
33:57 - 34:20

If you wish to ask a question, please dial pound five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Luisa Morgado from Van Lanschot Kempen. Please go ahead.

Peter
34:22 - 34:28

Yeah. So this is Peter. No, no, no, no. Oh, sorry. Sorry.

Anders Martin-Löf
34:29 - 34:30

Go ahead. Louisa.

Luisa Morgado
34:31 - 34:35

Oh. Hi, Jim. Thank you for taking my questions. Can you hear me? Yes.

Unknown 1
34:35 - 34:36

Yes. Yes, I can hear you.

Luisa Morgado
34:37 - 34:38

You can hear me?

Unknown 1
34:38 - 34:39

Yes.

Luisa Morgado
34:41 - 35:16

Oh, okay. Perfect. Hi. Thank you for taking my questions. Uh, first of all, congrats on the BrainTransporter data. And on that note, my first question. Could you please elaborate a bit on the results that you shared in terms of how I should look at the benchmarks that should be used here, but also to understand a bit better how or if this technology would produce a similar increase in terms of brain exposure with any other A-beta antibody. Or does that depend on each antibody? So if you could elaborate a bit here please.

Unknown 1
35:18 - 35:19

So I think.

Gunilla Osswald
35:19 - 35:21

We hand over to Pio Fresco. Please, Theo.

Peter
35:21 - 36:55

Yeah. Thanks for the question. And it's quite an important question, obviously. And I mean, we are also using the transferrin receptor for crossing the blood-brain barrier. And we think, based on our non-human primate studies and the results we see, that we achieve at least as much as other competitors, and potentially even more. And that could be due to the way we engage with the transferrin receptor. We're using quite a novel binding site on the receptor. As you mentioned, we bind to the protease-like domain, which is very close to the cell membrane, and that sort of hides the molecule when it binds to the transferrin receptor on the blood side, ensuring that it doesn't engage with the immune system. So we expect at least the same potency and delivery of our antibody. And also due to this novel binding site on the receptor, as we have engineered from the start, we also expect to have a more improved safety profile.

Gunilla Osswald
36:57 - 37:17

So I think in short, we stand very well in the competition. And also I think that what we have seen now exemplified with this A-beta antibody, linked to the BrainTransporter, we expect that to be a similar situation for other BrainTransporter-linked antibodies.

Unknown 1
37:23 - 37:25

Was that the answer to your question, Louisa? Okay.

Luisa Morgado
37:25 - 37:49

Thank you. That's quite helpful. And, um, please correct me if I'm wrong. Yes, definitely. And, uh, please correct me if I'm wrong, but, um, you will likely share further data on the BrainTransporter technology at AD/PD next year. Uh, if so, what kind of data update can we expect here?

Peter
37:50 - 38:17

Yes. So we plan to share more data around our most advanced program, where we're using the BrainTransporter technology. So it's based on the BAN2401 program that we're running, which is in the IND phase now. Further additional data will come regarding CMC and developing timelines for that program.

Luisa Morgado
38:26 - 39:02

Okay. Perfect. And, um, maybe one final question regarding the blood-based diagnostics. Um, could you expand a bit on. So what do you foresee over the coming years? How do you see it playing out in terms of using the blood-based biomarkers with other kinds of biomarkers across imaging? When should we expect that they are starting to be used alone? Uh, and overall impact on, um, adoption of Leqembi.

Gunilla Osswald
39:04 - 39:52

Very good question. Thank you for that. So I think right now it's mainly being used for screening, which helps to identify which patients should then be confirmed by CSF or PET scan. But as was presented at the ADPD. The time is approaching when you can also use the blood-based biomarkers directly for confirmation. So I don't think that's far away. I think we'll start to see that happen next year and onwards. So I think, I mean, it's really, I think it's time now. And that will really help to find patients in an easier way. I think the first step with screening is really good, but it's really the confirmatory process that would be really, really helpful. So, it's soon here.

Luisa Morgado
40:00 - 40:02

Okay. Perfect. Thank you so much. That's all from my side.

Unknown 1
40:03 - 40:04

Thank you so much, Luisa.

Operator
40:07 - 40:12

The next question comes from Victor Sundberg from Nordea. Please go ahead.

Victor Sundberg
40:19 - 41:09

Yes. Hi. Thanks for taking my question. So just one question here on the BrainTransporter technology. I think your previous experiments have shown, quite a different profile when comparing therapeutic doses of brain transporter antibodies versus trace dosing targeting the transferrin receptor, where some of your competitors have shown 40 times higher exposure at trace dosing, but only 1.5 times higher at therapeutic doses, which was explained in your patent documents. So just wondered how you compare at therapeutic doses versus trace dosing in your more recent experiments that you showed here? I think your patent documents mentioned ten times higher exposure at therapeutic doses and 80 times higher at trace dosing compared to a naked antibody. And if I read it correctly. So just wanted to get a clarification on that. Thank you.

Unknown 1
41:10 - 41:11

Yeah. Thank you, Victor.

Gunilla Osswald
41:11 - 41:13

So, I think Pierre will answer the question.

Unknown 1
41:13 - 41:14

Yeah.

Peter
41:14 - 41:20

Yeah. Thanks for the question. I think it's important to understand. So, the fold improvement that we disclosed now is based on the nonhuman primate study, and that it's done quite differently compared to when you do the study in rodents and in the nonhuman primate study, we use therapeutic dosing, which is relevant for clinical use.

Unknown 2
41:20 - 41:20

Fold.

Peter
41:20 - 42:12

The improvement that we disclosed now is based on the nonhuman primate study, and it's done quite differently compared to when you do the study in rodents. And then we compare that, obviously, with the same antibody without a brain transporter linked to it. So the figure we disclosed now is the more relevant one for clinical application. And also, it's based on a sort of a more translatable animal model, if you like. So, that figure is, uh, yes. The most recent figure that we have disclosed is the most relevant one, I would say.

Victor Sundberg
42:19 - 42:39

Okay. Thank you very much. Um, and just curious, um, if you heard any rumors why Biogen handed back the rights to Denali for a similar brain transporting technology. Was that maybe safety-related, as you talked about or hinted at, in your previous comments? Thank you.

Peter
42:41 - 42:54

I don't think I can comment on that, actually. What you mentioned was that it was not related to safety or efficacy in the press release, but obviously, you hear some rumors, but we don't.

Gunilla Osswald
42:54 - 42:55

We don't comment on that kind.

Peter
42:55 - 42:58

Obviously, that is the case. So I pass on that.

Victor Sundberg
43:05 - 43:07

Okay. Thank you very much.

Unknown 1
43:07 - 43:08

Thank you, Victor.

Operator
43:12 - 43:16

The next question comes from Joseph Hedden from WR Securities. Please go ahead.

Joseph Hedden
43:24 - 44:04

Hi there, thanks for taking my questions and congrats on what looks like really interesting BrainTransporter data. Um, just a question on the potential EU milestone. If you do get a positive CHMP tomorrow, can you confirm if that would be around the same level as you would have expected for a first-time approval? And can you just remind us of what kind of ballpark that is? Um, and then the second question, if again, if you do get a positive CHMP opinion, when would you expect that you could make the first launches in the Nordic under your co-promotion agreement with Eisai? Thank you.

Unknown 1
44:06 - 44:07

So will you take the first one?

Anders Martin-Löf
44:07 - 44:30

I can take the first question. And also it's based on a more translatable animal model, if you like. So it's known that we were paid $25 million when we got the approval in the US and $17 million when we got it in Japan, and the EU will be somewhere in between. And it doesn't matter if it has been re-examined or not, that has no impact on the size of the milestone. As for the second question, we should probably ask Nakaya to.

Unknown 3
44:30 - 44:31

To.

Anders Martin-Löf
44:31 - 44:32

I'll give you an update.

Unknown 1
44:32 - 45:09

Yes. And just to mention initially, of course, the market access process is led by Eisai. And when it comes to hospital products, there are no exact timelines. So, they are kind of estimates. So if we get European Commission approval at the beginning of next year, it might take anywhere from 6 to 18 months. So, so but I'm, you know, hoping that we could launch early 2026, something like that. In one of the countries, which is, and then. Okay. Thanks very much.

Joseph Hedden
45:09 - 45:10

Much. Yeah.

Gunilla Osswald
45:11 - 45:12

Thank you so much, Joseph.

Unknown 4
45:13 - 45:14

Yes.

Joseph Hedden
45:18 - 45:19

Thank you.

Operator
45:19 - 45:25

The next question comes from Natalia Webster from RBC Capital Markets. Please go ahead.

Natalia Webster
45:30 - 45:58

Hi there. Thanks for taking my question. I just have a follow-up around the timeframes for your BrainTransport technology. I appreciate all the data and the sort of differentiators that you've mentioned, but we've heard from Roche that it expects to select a Phase 3 dose next year, and they're suggesting a potential filing date in 2028. I wanted to understand broadly how far behind Roche you think your Alzheimer's project is.

Gunilla Osswald
46:00 - 46:34

Thank you so much for the question. So our most advanced BrainTransporter program is in Alzheimer's disease. And there we are about two years away from entering the clinical setting. So, 2026 is what we expect to go into the clinical setting. And then I think we can learn so much both from Lecanemab and Donanemab and others. So, I think there is an opportunity to execute a really good clinical development program. But I will not say any more dates than that. We expect to enter 2026 with the first one completed.

Natalia Webster
46:41 - 46:42

Great. Thank you.

Gunilla Osswald
46:43 - 46:44

Thank you so much.

Operator
46:52 - 46:56

The next question comes from Fredrik Thore from Redeye. Please go ahead.

Fredrik Thore
47:02 - 47:25

Hello and thank you. My first question was about whether Leqembi might not be approved in the re-examination. Do you have any expectations on what kind of new data you would have to send in? For example, could real-world data be enough for a resubmission? Or would you probably need to conduct a new clinical trial, or would Eisai need to do so?

Gunilla Osswald
47:27 - 47:51

Thank you so much for the question, Fredrik. I think it depends very much on what happens. Uh, we will know by tomorrow, um, what the outcome is, and then we'll have to digest and understand if it's not a positive outcome. We need to understand, um, why it's not a positive one. And then we will have to take it from there.

Fredrik Thore
47:58 - 48:39

Got it. And our final question was about, um, the bottleneck here being the infusion capacity. As I mentioned, they will increase it in Q4 and in Q1. Uh, do you have any expectations on your own about how fast that will be? And for example, when it comes to the remaining sales in the forecast that is given, should we expect it to be kind of even between Q4 and Q1, or will sales increase more in Q1, for example, if the bottleneck is very much present now?

Anders Martin-Löf
48:41 - 49:25

Thanks for the question. So, yes, we are expecting, of course, continued growth. So we'll see a little less sales in Q4 of this year and a little bit more in the first quarter of next year. In terms of how fast the bottlenecks will be resolved, we can't comment more than Eisai's expectation that the 6,000 patients currently waiting for treatment will be treated in the coming two quarters. Uh, but they have contracted capacity that will come online in the two following quarters, although exactly when in those two quarters has not been communicated. And we don't have any opportunity to comment more on that.

Gunilla Osswald
49:25 - 49:30

But we have seen press releases about companies that have been contracted. So I think it's happening.

Unknown 3
49:31 - 49:32

Yes, yes.

Fredrik Thore
49:39 - 49:40

Perfect. Thank you.

Gunilla Osswald
49:40 - 49:42

Thank you so much, Frederick.

Operator
49:51 - 49:57

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad.

Unknown 4
50:03 - 50:04

So.

Peter
50:05 - 50:05

Oscar here.

Oskar Bosson
50:05 - 50:41

It doesn't seem like there are any more people in queue right now, so I'll just go and look through the written questions. And we have one, Gunilla. I'm not sure if you're able to comment, but the question is from Goldman Sachs, and he's asking, what's your level of confidence? And in Leqembi European approval, is there a potential for the CHMP and other local regulators to take a similar strategy as the UK with the approval, that is, without the ApoE4 homozygotes?

Gunilla Osswald
50:42 - 50:58

So, I don't think anyone knows yet. I mean, we just have to wait until tomorrow when we will have the information from the CHMP, and I don't want to speculate or comment anything more. I mean, we just have to wait until tomorrow.

Oskar Bosson
50:59 - 51:26

Okay. Thank you. And then there's another question again from Max at Goldman Sachs. And it's about, um, ARIA and pre-symptomatic patients. So specifically in the AHEAD 345 study. And he wants to know if we know if there's any correlation between stage or severity of the disease and ARIA. And if you know, how confident are we about whether regulatory agencies would be concerned about ARIA in the very early patients.

Gunilla Osswald
51:29 - 51:59

To my knowledge, there has not been any correlation between stage and severity like that. Um, and um, I think that what we hear and heard at CTAD was that the key opinion leaders who have been using Leqembi in clinical practice think this is manageable. So I think we need to continue to follow this closely.

Oskar Bosson
52:01 - 52:17

Thank you. There was an additional question too from Max. And that was about the differentiation of our technology relative to competitors. Um, when it comes to the brain transporter. But I believe you already answered that question previously.

Gunilla Osswald
52:20 - 52:29

Yeah. We have a unique technology to our knowledge. So really exciting data. So we really look forward to that part.

Oskar Bosson
52:31 - 52:44

And then another question that just popped up. And maybe that's for Anders or Annika. And what's our expectation for the market of Leqembi in Europe? If there were to be a positive opinion and an approval, what would be the implications?

Anders Martin-Löf
52:46 - 53:35

Thank you. Well, we can just revert to Eisai's forecast. They do that once every year. And they did that at the beginning of this year, where they basically said that roughly 6% of Leqembi sales in 2026 were expected to come from Europe, and that number would grow to 14% in 2032. I think so. So it is, of course, an important market. But out of the whole Leqembi market, it has a limited potential, especially in the near term. But of course, that does not mean that it's unimportant to us. We certainly hope that Leqembi will get approval in Europe and that we will be able to help the patients in Europe. Hope that answers the question.

Oskar Bosson
53:37 - 53:57

Thank you. I don't see anybody else in the queue on the phone, and I also do not see any more questions in the written questions section. So I think, um, I think that sort of concludes. Gunilla, do you want to say anything? Any final words?

Gunilla Osswald
53:58 - 54:06

No, I'll just say thank you so much for your attention and for all the great questions. And I wish you a great rest of the day and cross our fingers for tomorrow. Thank you so much.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…